Co-Diagnostics (HAM:C970) Cyclically Adjusted FCF per Share: €-6.95 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:C970 Co-Diagnostics Inc HAM:C970
63 GF Score
Price €5.55
GF Value €7.87
! 5 Warning Signs
View Full Analysis

What is Co-Diagnostics Cyclically Adjusted FCF per Share?

Co-Diagnostics HAM:C970 63 Cyclically Adjusted FCF per Share is €-6.95 as of Jun. 2026. GuruFocus rates HAM:C970 with a GF Score™ of 63/100 and a GF Value™ of €7.87. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Co-Diagnostics's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-1.444. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-6.95 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

As of today (2026-08-25), Co-Diagnostics's current stock price is €5.55. Co-Diagnostics's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-6.95. Co-Diagnostics's Cyclically Adjusted Price-to-FCF of today is .


Co-Diagnostics  (HAM:C970) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Co-Diagnostics Cyclically Adjusted FCF per Share Related Terms


Co-Diagnostics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Co-Diagnostics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Co-Diagnostics Cyclically Adjusted FCF per Share Chart

Co-Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -3.75

Co-Diagnostics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -2.58 -3.75 -11.16 -6.95

HAM:C970 vs HSCS, NVNO, SINT: Cyclically Adjusted FCF per Share Comparison

For the Medical Devices subindustry, Co-Diagnostics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Co-Diagnostics Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Co-Diagnostics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Co-Diagnostics's Cyclically Adjusted Price-to-FCF falls into.


HAM:C970
63GF Score
Co-Diagnostics Inc HAM:C970
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Co-Diagnostics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Co-Diagnostics's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-1.444/333.9520*333.9520
=-1.444

Current CPI (Jun. 2026) = 333.9520.

Co-Diagnostics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.713 241.428 -0.986
201612 -1.413 241.432 -1.954
201703 -1.155 243.801 -1.582
201706 -0.705 244.955 -0.961
201709 -3.327 246.819 -4.502
201712 -2.122 246.524 -2.875
201803 -1.932 249.554 -2.585
201806 -2.017 251.989 -2.673
201809 -2.453 252.439 -3.245
201812 -2.044 251.233 -2.717
201903 -2.261 254.202 -2.970
201906 -2.074 256.143 -2.704
201909 -1.908 256.759 -2.482
201912 -2.624 256.974 -3.410
202003 -1.707 258.115 -2.209
202006 0.806 257.797 1.044
202009 7.274 260.280 9.333
202012 16.497 260.474 21.151
202103 10.189 264.877 12.846
202106 10.203 271.696 12.541
202109 9.661 274.310 11.762
202112 4.209 278.802 5.042
202203 5.815 287.504 6.754
202206 1.002 296.311 1.129
202209 0.859 296.808 0.966
202212 -4.120 296.797 -4.636
202303 -5.793 301.836 -6.409
202306 -5.809 305.109 -6.358
202309 -5.745 307.789 -6.233
202312 -4.896 306.746 -5.330
202403 -8.222 312.332 -8.791
202406 -4.907 314.175 -5.216
202409 -6.566 315.301 -6.954
202412 -7.707 315.605 -8.155
202503 -7.654 319.799 -7.993
202506 -6.824 322.561 -7.065
202509 -4.034 324.800 -4.148
202512 -2.870 324.054 -2.958
202603 -3.067 330.213 -3.102
202606 -1.444 333.952 -1.444

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-6.95 mean?
Co-Diagnostics (HAM:C970) has a Cyclically Adjusted FCF per Share of €-6.95 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Co-Diagnostics and its competitors.
Is Co-Diagnostics' Cyclically Adjusted FCF per Share too high?
Co-Diagnostics' current Cyclically Adjusted FCF per Share is €-6.95. Overall, Co-Diagnostics has a GF Score™ of 63/100, reflecting its overall financial health beyond just this single metric.
How does Co-Diagnostics' Cyclically Adjusted FCF per Share compare to HSCS and NVNO?
Co-Diagnostics' Cyclically Adjusted FCF per Share of €-6.95 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Co-Diagnostics and its competitors. Co-Diagnostics's current Cyclically Adjusted FCF per Share is €-6.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Co-Diagnostics stock overvalued right now?
Co-Diagnostics (HAM:C970) has a current Cyclically Adjusted FCF per Share of €-6.95. The stock's GF Value™ is €7.87, compared to a current price of €5.55 — trading 29.5% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €-6.95. Co-Diagnostics' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Co-Diagnostics (HAM:C970), the current Cyclically Adjusted FCF per Share is €-6.95 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Co-Diagnostics (HAM:C970) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be undervalued. The current stock price of €5.55 is trading 29.5% below its estimated GF Value™ of €7.87.

Key valuation signals for HAM:C970:

  • Cyclically Adjusted FCF per Share: €-6.95
  • GF Value™: €7.87 vs. price of €5.55 (29.5% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Co-Diagnostics Business Description

Other Exchanges CODX:USA0A50:UK
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score

Get the complete analysis for HAM:C970

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.55
Price
€7.87
GF Value